Tag: Eluvia
Boston Scientific announces position on FDA update about use of paclitaxel-coated...
Following yesterday's news that the US Food and Drug Administration (FDA) has changed its stance on the use of paclitaxel-coated devices to treat peripheral...
Evidence in the SFA: What kind of stent should we use?
NOTE: This video is ONLY available to watch in selected countries and geographies
Antonio Micari (interventional cardiologist, Italy) gives his thoughts on the EMINENT...
Evidence in the SFA: Best strategy for treatment of the femoropopliteal...
NOTE: This video is ONLY available to watch in selected countries and geographies
Yann Goueffic (vascular surgeon, France) discusses the evidence that is needed...
EMINENT one-year results show “superior” primary patency rate for Eluvia DES...
One-year results presented at Vascular Interventional Advances (VIVA) 2021 (5–7 October, Las Vegas, USA) from the EMINENT trial demonstrated the superiority of the Eluvia...
CMS grants additional reimbursement for the Eluvia drug-eluting vascular stent system
Boston Scientific announced that the US Centers for Medicare and Medicaid Services (CMS) granted a new technology add-on payment (NTAP) for the Eluvia drug-eluting...
Endovascular intervention for the treatment of femoropopliteal lesions: ELUVIA is safe...
This advertorial is sponsored by Boston Scientific.
Boston Scientific leads the largest clinical programme investigating drug-eluting therapy for the treatment of peripheral arterial disease (PAD),...
CIRSE 2019: Hear the latest from clinical trials comparing paclitaxel technologies...
NOTE: ONLY intended for healthcare professionals outside of the USA and France.
Zoom in on a tête-à-tete between Marianne Brodmann (Graz, Austria) and Giovanni Torsello...
Only Eluvia Uses a Polymer for Controlled, Targeted Delivery of the...
Eluvia DES is the only technology that uses polymer-based drug delivery to treat Peripheral Artery Disease (PAD). Its polymer ensures that the majority of...
Positive outcomes for Eluvia stent in long lesion IMPERIAL sub-study
Clinical outcomes from the IMPERIAL Long Lesion Sub-study were presented at VIVA (5–8 November, Las Vegas, USA) demonstrating that the Eluvia drug-eluting vascular stent...
Eluvia outperforms Zilver PTX in IMPERIAL 12-month results
The Eluvia drug-eluting vascular stent system (Boston Scientific) shows superior primary patency compared to the Zilver PTX drug-eluting stent (Cook Medical), concludes the 12-month...
Eluvia paclitaxel-eluting stent shows long-term freedom from revascularisation at three years
Boston Scientific has announced the three-year results from the MAJESTIC trial for the Eluvia paclitaxel-eluting vascular stent system at the Cardiovascular and Interventional Radiological...
